Jaguar8 commented on a stock · Aug 28, 2024 04:30

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals (Nasdaq: EGRX) received a delisting notification from Nasdaq on August 21, 2024, due to its failure to timely file the Q2 2024 Form 10-Q. This follows a previous notice on August 1, 2024, where Nasdaq granted the company continued listing subject to specific conditions. Eagle must file its 2023 Annual Report by September 30, 2024, and both Q1 and Q2 2024 Form 10-Qs by October 31, 2024. The company plans to file a comprehensive Form 10-K, including restated financial information, and separate Form 10-Q filings to meet these deadlines. However, there's no guarantee that Eagle will meet the compliance dates or maintain its Nasdaq listing.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

3929 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8176

Followers

Following

93K

Visitors